Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 166591-85-1 | MDL No. : | MFCD08274995 |
Formula : | C15H19NO4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | KMTRFKAFNRHBCH-UHFFFAOYSA-N |
M.W : | 277.32 | Pubchem ID : | 15280723 |
Synonyms : |
|
Num. heavy atoms : | 20 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.47 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 78.2 |
TPSA : | 66.84 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.26 cm/s |
Log Po/w (iLOGP) : | 2.47 |
Log Po/w (XLOGP3) : | 2.44 |
Log Po/w (WLOGP) : | 1.9 |
Log Po/w (MLOGP) : | 1.83 |
Log Po/w (SILICOS-IT) : | 1.47 |
Consensus Log Po/w : | 2.02 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -3.05 |
Solubility : | 0.245 mg/ml ; 0.000882 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.49 |
Solubility : | 0.0904 mg/ml ; 0.000326 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.6 |
Solubility : | 0.689 mg/ml ; 0.00248 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.0 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With triethylamine In dichloromethane at 0 - 20℃; | To a stirring mixture of (±)-l,2,3,4-tetrahydroisoquinoline-l-carboxylic acid (150 mg, 0.85 mmol) and CH2C12 (1.69 mL) at 0 °C, add di-tert-butyldicarbonate (185 mg, 0.85 mmol) and triethylamine (177 xL, 1.27 mmol). Allow the mixture to warm to room temperature with stirring overnight. Add an aqueous solution of HCl (1.0 N) until the pH reaches 3.0, then extract the mixture with EtOAc (3 x 25 mL). Wash the combined organic phases with saturated aqueous NaCl (50 mL), dry over MgS04, filter, and concentrate the filtrate under reduced pressure to furnish the title compound (235 mg, 100percent yield). Mass spectrum (m/z): 222 (M + 2H - t-Bu)+, 300 (M + Na)+, 577 (2M + Na)+. |
85% | With triethylamine In tetrahydrofuran; water | STEP A N-[(1,1-Dimethylethoxy)carbonyl]-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid Di-tert-Butyldicarbonate (Boc2 O, 8.2 g, 37.6 mmol, 1.1 eq.) was added to a stirred solution of 1,2,3,4-tetrahydroisoquinaldic acid [prepared from isoquinoline-1carboxylic acid according to W. Solomon, J. Chem. Soc., 1947, 129), 6.0 g, 33.8 mmol]and NEt3 (5.2 ml, 37.6 mmol, 1.1 eq.) in 50 ml of tetrahydrofuran and 50 ml of water. The mixture was stirred at room temperature for 16 hours, when tetrahydrofuran was evaporated. The residual aqueous phase was acidified (solid citric acid) and the protected amino acid extracted with AcOEt (three times). The combined organic layers were washed with brine, dried over MgSO4 and evaporated (20 Torr, 30° C. and 0.01 Torr, 20° C.) to afford 8.0 g (85percent) of the protected amino acid. |
[ 151838-62-9 ]
2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Similarity: 0.97
[ 321983-19-1 ]
1-(tert-Butoxycarbonyl)-3-phenylpiperidine-2-carboxylic acid
Similarity: 0.87
[ 151004-88-5 ]
(R)-N-Cbz-3,4-dihydro-1H-isoquinolinecarboxylic acid
Similarity: 0.86
[ 151838-62-9 ]
2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Similarity: 0.97
[ 321983-19-1 ]
1-(tert-Butoxycarbonyl)-3-phenylpiperidine-2-carboxylic acid
Similarity: 0.87
[ 151004-88-5 ]
(R)-N-Cbz-3,4-dihydro-1H-isoquinolinecarboxylic acid
Similarity: 0.86
[ 151838-62-9 ]
2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Similarity: 0.97
[ 151004-88-5 ]
(R)-N-Cbz-3,4-dihydro-1H-isoquinolinecarboxylic acid
Similarity: 0.86
[ 170097-67-3 ]
2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid
Similarity: 0.79
[ 149353-95-7 ]
2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid
Similarity: 0.79
[ 622867-52-1 ]
tert-Butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Similarity: 0.76